,,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['destiny-04', 'thanks', 'breast', 'enhertu']
sunday #asco2022 highlights from our s+r team...quick strategy session thanks to #boehringeringelheim, indulging in sweet treats and a standing ovation for the phase lll destiny-04 her2 low abstract presentation! huge news for metastatic breast cancer patients! #enhertu 
Research + Strategy = Insights + Ideas. Helping clients find new pathways to grow since 1955